Eli Lilly and Co. has agreed to use a continuous glucose monitoring device from DexCom Inc. with the pharmaceutical giant's insulin delivery devices for patients with diabetes.
The nonexclusive deal will see San Diego-based DexCom's glucose monitors used along with Lilly's pen- and pump-based systems under development.
Dexcom's devices measure blood sugar for patients with diabetes to determine the need for insulin. The monitoring system will provide blood sugar data for the patient to either administer their own insulin with Lilly's pen or feed that information into a closed-loop system connected to an insulin pump that automatically injects insulin.
For diabetes in particular, drug and device makers often collaborate to manage the disease, which requires dependable administration of insulin and can be a burden to patients. DexCom, which worked with Indianapolis-based Lilly to co-develop the automated insulin system, received U.S. approval for its newest glucose monitor in 2018.
Financial details of the commercialization agreement were not disclosed in a Dec. 16 press release announcing the deal.